PerkinElmer to Triple Neonatal Screening Capacity in Mexico
News Jul 22, 2008
PerkinElmer, Inc. has announced a one-year agreement with the Mexican Ministry of Health, la Secretaria de Salud, to expand its newborn screening program across Mexico.
Under the terms of the agreement, PerkinElmer will provide instrumentation, reagents and screening expertise that will help the Ministry of Health screen for congenital hypothyroidism and triple its screening capacity. The expanded program began in May 2008.
“We are honored to have been selected by the Mexican Ministry of Health to support the continued growth of its neonatal screening program,” said Robert F. Friel, president and chief executive officer, PerkinElmer, Inc.
“PerkinElmer is the world’s leading supplier of newborn screening systems and remains committed to supporting the expansion and standardization of newborn screening programs worldwide with technology to allow for early detection of potentially life-threatening disorders.”
Approximately 2.4 million babies are born each year in Mexico, which has a population of about 110 million. In 2007, PerkinElmer provided technology to screen approximately 640,000 newborns in 14 laboratories across Mexico. Under this new agreement, that number will increase to approximately 1.9 million tests per year.
Additionally, PerkinElmer will continue to collaborate with Mexican health authorities to assist them in further developing and expanding their program in the coming years.
Through this agreement, the Mexican Ministry of Health will use PerkinElmer’s DELFIA® and AutoDELFIA® Neonatal TSH (hTSH) kits, and VICTOR™ platform to screen for congenital hypothyroidism (CH) in newborns. CH is an inherited metabolic disorder which occurs in 1 in 3,000-6,000 babies worldwide. If left untreated, CH can lead to severe mental retardation.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019